Basics of Radiopharmacy

Total Page:16

File Type:pdf, Size:1020Kb

Basics of Radiopharmacy 4- A .1- A r A I Basics of radiopharmacy BUCK A. RHODES, Ph.D. Director of Radiopharmacy, University of New Mexico College of Pharmacy, Albuquerque, New Mexico BARBARA Y. CROFT, Ph.D. Division of Nuclear Medicine, University of Virginia Medical Center, Charlottesville, Virginia with 246 illustrations, including drawings by Mark Prouse The C. V. Mosby Company SaintLouis 1978 Copyright @ 1978 by The C. V. Mosby Company All rights reserved. No part of this book may bc rcproduced in any manner without written permission of the publisher. Printed in the United States of America ’Ihe C. V. Mosby Company 1 1x30 Westline Industrial Drive, St. Louis, Miswuri 63141 Library of Congress Cataloging in Publication Data Rhodes, Buck A,, 1935- Basics of radiopharmacy. Includes bibliographies and index. 1. Radiopharmaceuticals. 1. Croft, Barbara Y., 1940- jointauthor. 11. ‘litle.[DNLM: I. Nuclear medicine. 2. Radioisotopes--l)iagnostic use. 3. Radioisotopes-Therapeutic IISC. WNW R476bl RM825.R46615’.8424 77-26557 ISBN0-8016-4127-6 CW/M/M 9 X 7 6 5 4 3 2 I Foreword The evolution of radiopharmacy as a special- Even as the discipline of radiopharmacy de- ty has been extremely rapid when compared to velops, its future will be molded by many in- other disciplines within pharmacy. Essentially ternal and external forces and pressures. These it has developed as aspecialty area within a pressures includefederal regulatory actions period of 20 ycars, and its route has been tor- concerningradiopharmaceuticals, actions of tuous. The preparation, dispensing, and clinical state boards of pharmacyconcerning radio- investigation of radioactive materials as drugs pharmacies and radiopharmaceuticals, new di- started experimentally early in the 1950s with rections of research in imaging in nuclear medi- the use of I3'l and a2P.As the early use of these cine, new directions in radiopharmaceutical de- and other nuclides evolved and as the impor- velopment, and the numbers and direction of tance of labeled compounds as imaging agents educational program in radiopharmacy by col- bccame recognized,primary development of leges of pharmacy. It is certain that these forces radiopharmaceuticals lay with the research ra- and pressures among others will dictate many diochemist and physician. In the late 1960s and dramatic changes and developments within ra- early 1970s, however, nuclear medicine devel- diopharmacy in the forseeable future. oped as a separate medical specialty and began With their extensiveexperience in and to expand dramatically. With this development knowledge of the field of radiopharmacy, the came a whole regiment of new radiopharma- authors of Basics oj Radiopharmucy have ceuticals. The proliferation of these radioactive clearly defined the functions and types of pro- imaging agcntsrequired the parallel dcvelop- fessional activities that the radiopharmacist per- ment of specialists qualified to prepare, run forms. Thistextbook provides a current and quality control on, run clinicalstudies on, detaileddescription of the basics of radio- and dispense these agents. In short, by evolu- pharmacy and theessential knowledge base tion radiopharmacy and the radiopharmacist needed for the student intending to enter this emerged as an essentialdiscipline and asa field. It also will serve as an important refer- partner to nuclear medicine and the nuclear ence book for educators and others who wish medicine physician, to expand their knowledge of radiopharmacy Today radiopharmacy is viewed as a distinct but who may not be actively involved in prac- discipline. While constant interaction and close tice. 1 congratulate the authors on a very cow- cooperative ties between the nuclear rnedicinc plete text, well organized and well written. This physician andthe radiopharmacistare essen- text should be a valuable addition to the excit- tial, the functions of radiopharmacists are be- ing and interesting new specialty of radiophar- coming more defined, and their distinct role as macy . clinicians and as distributors of radiopharma- Carman A. Bliss, Ph.D. ceuticals is evolving rapidly. Dean, Universiry of New Mexico College of Pharmucy, Albuquerque, New Mexico V Preface Basics of Radiopharmacy was written to pro- physics. Although knowledge of these subjects vide a first-coursetextbook in radiopharmacy is assumed, an outline of prerequisite knowl- for use by undergraduates in pharmacy and nu- edge is given in the Appendix. Our experience clear medicine technology. The text is planned in teaching this class over the past years is that as a comprehensive introductionto the prepara- a few review sessionsare sometimes neces- tion and clinicaluse of radioactivetracers. sary to prepare the students for this course. Tracer principles are combined with pharmacy The outline of material was developed from techniques to provide the student with the in- courses presented at the University of Virginia, formation needed to prepareradioactive sub- TheJohns Hopkins Medical Institutions,the stancesfor intravenous administration to pa- University of Kansas, and the University of tients. New Mexico. The text assumes that the student will have an understanding of chemistry and basic atomic Buck A. Rhodes Barbara Y. Croft vii Contents 1 What is radiopharmacy? 1 Mechanisms of localization, 33 Definitions, 1 The magic bullet approach versus the tracer Radiopharmacy, 1 concept, 33 Radiopharmaceuticals, 3 Capillary blockage, 36 Radiopharmacists, 5 Phagocytosis, 40 Nuclear medicine, 6 Cell sequestration, 42 History of radiopharmacy, 7 Active transport, 44 Radiopharmacy compared to pharmacy in Compartmental localization, 47 general, 1 1 Simple or exchange diffusion, 48 ‘Types of radiopharmacics, 14 Missing mechanisms, 48 Hospital radiopharmacics, 14 Blood flow and tracer localization, 50 Central radiopharmacies, 14 Training radiopharmacists, 14 of Design criteria, 52 Physical characteristics, 52 Chcmical and biologic characteristics, 56 2 Tracer techniques in Solubility, 58 medicine, 17 Tagging reactions, 58 In vivo stability, 59 ‘Tracer tcchniques: uses and advantages, 17 Clearance, h 1 Usc of tracers to dctermine Inass and space,19 Amount of tracer, 61 Law of conservation of matter, 19 Elements by groups in the pcriodic chart, 62 Group 1, 65 Red cell mass, 19 Groups 2 and 65 Volumes of distribution, 21 3, Groups 4 to 66 Use of traccrs to determinc ratcs and 6, Esscntial tracc elements and nonessential pathways, 23 transition metals, 66 Dynamic studies and nuclear Group 7, 68 angiography, 24 Group 0: thc noble gases, 69 Tracer clearance as a measure of blood Row, 24 Heavy metals and rare earths, 70 Bifunctional compounds designed for use Indicator concentrations and transits as as radiopharnlaceuticals, as 73 ! measures of hlood flow, 26 Absorption, metabolism, and turnover studics, 27 Making radiopharmaceuticals!’ Use of tracers in quantitative microanalysis, safe and effective, 76 27 Isotope dilution analysis, 28 Preliminary hiodistribution sludies, 76 Substoichiomctric analysis, 29 Checking systcm for sterility and Isotopic equilibrium analysis, 3 I apyrogenicity , 77 Activation analysis, 32 Sterilization, 78 ix X Contents Sterility testing, 78 9 Generatorsystems, 1 13 Pyrogens and the pyrogen response, 79 Pyrogen testing, 79 General characteristics, 113 Toxicity studies, 83 Construction, I 14 Introducing new radiopharmaceuticals, 86 Operation, 116 The IND, 86 99Mo/99mTc generator, 1 I7 Clinical trials, 87 Description, 117 Replacing old radiopharmaceuticals, 88 Evaluation of eluate, 119 Adverse reactions to radiopharmaceuticals, 113Sn/113mIn generator, 121 88 Description, 121 Overdosing and underdosing, 89 Evaluation of eluate, 121 Injection problems, 89 Generators for ultrashort-lived nuclides, 12 I Uses, 121 Examples:'31Cs/137mBa, 81Rb/M1mKr,and 6 Radiationtherapy with 8iSr/82Rb. 122 radiopharmaceuticals, 91 Design, 91 10 Production of radiochemical$, 123 1311, 91 Basic concepts, I23 32Psodium phosphate, 91 Radioiodination, 123 Colloids, 9 1 Technetium chemistry, 126 Handling therapy patients, 92 Reduction, 126 Assurance of radioisotope dosage, 92 Ligand exchange, I27 Radiation safety considerations, 92 Chelation, 128 Talking with the patient, 93 F'rotein labeling, 130 Sulfur-based reduction products, 130 7 Radiationdosimetry, 95 Chelation and complexation of other metals, 13 I Early observations of radiation effects, 95 Organic and biochemical synthesis, 132 Review of radiation biology, 95 Biologic synthesis, 133 Review of the properties of radioactive materials and absorption of radiation, 96 Dosimetry calculations, 98 11 Daily preparations and their Physical and biologic contributions, 98 quality control, 136 Sample calculation, 102 Summary, I03 Routine quality control, 136 General requirements, 136 8 Production of radionuclides, Thin-layer chromatography, 136 Gel-columnscanning, 137 105 Sodium pertechnetate solution, 138 Activation of stable elements, 105 Elution volume, 139 Calculation of production rates and Assay of total radioactivity, 139 reactor production, 105 Assay of radionuclidic purity, 140 Separation techniques, 106 Assay of radiochemical purity, 141 Specific activity, 107 Specific activity, 141 Example: lSF from LiCO,, 107 Aluminumbreakthrough, 142 Linear accelerator and cyclotron Labeling and record keeping, 142 production, 107 99mTccolloids, 142 "C, 13N, I5O, 11 1 99mTclung agents, 144 Halogens (1231 as an example), 1 1 1 99mTc bone agents, 144 Other cyclotron-produced nuclides, 11 1 99mT~DTPA, 145 Fission production, 11 1 99mTcHSA, 146 9rmT~RBCs, 146 YPmTcWCs, 147 Contents
Recommended publications
  • Managing Terrorism Or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: a Comprehensive Review
    Int. J. Environ. Res. Public Health 2014, 11, 4158-4200; doi:10.3390/ijerph110404158 OPEN ACCESS International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph Review Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review Eric R. Braverman 1,2,3, Kenneth Blum 1,2,*, Bernard Loeffke 2, Robert Baker 4, 5, Florian Kreuk 2, Samantha Peiling Yang 6 and James R. Hurley 7 1 Department of Psychiatry, College of Medicine, University of Florida and McKnight Brain Institute, Gainesville, FL 32610, USA; E-Mail: [email protected] 2 Department of Clinical Neurology, PATH Foundation NY, New York, NY 10010, USA; E-Mails: [email protected] (B.L.); [email protected] (F.K.) 3 Department of Neurosurgery, Weill-Cornell Medical College, New York, NY 10065, USA 4 Department of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA; E-Mail: [email protected] 5 Natural Science Research Laboratory, Museum of Texas Tech University, Lubbock, TX 79409, USA 6 Department of Endocrinology, National University Hospital of Singapore, Singapore 119228; E-Mail: [email protected] 7 Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-646-367-7411 (ext. 123); Fax: +1-212-213-6188. Received: 5 February 2014; in revised form: 26 March 2014 / Accepted: 28 March 2014 / Published: 15 April 2014 Abstract: Chernobyl demonstrated that iodine-131 (131I) released in a nuclear accident can cause malignant thyroid nodules to develop in children within a 300 mile radius of the incident.
    [Show full text]
  • Design of Neutron and Gamma Ray Diagnostics for the Start-Up Phase of the DTT Tokamak
    46th EPS Conference on Plasma Physics P5.1105 Design of neutron and gamma ray diagnostics for the start-up phase of the DTT tokamak M. Angelone 1, D. Rigamonti 2, M Tardocchi 2, F. Causa 2, S. Fiore 1, L. C. Giacomelli 2, G. Gorini 3,2 , F. Moro 1, M. Nocente 3,2 , M. Osipenko 4, M. Pillon 1, , M. Ripani 4, R. Villari 1 1ENEA, Centro Ricerche Frascati, Frascati, Italy 2Istituto per la Scienza e Tecnologia dei Plasmi, CNR, Milan, Italy 3Dipart. di Fisica “G. Occhialini”, Università degli Studi di Milano-Bicocca, Milano, Italy 4Istituto Nazionale di Fisica Nucleare, Genova, Italy e-mail : [email protected] Abstract The Divertor Tokamak Test (DTT) facility, which is under design for construction in Frascati (Italy), will produce neutron yield up to 1.3*10 17 n/s at full power (H-mode scenario). This calls for an accurate design and selection of the 2.5 MeV neutron diagnostic systems and detectors which can give the comprehensive exploitation of the high neutron fluxes. Measurements of 14 MeV neutrons (which are about 1% of the total neutron yield) coming from the triton burn-up will also be performed. DTT will reach its best performances after a preliminary phase , needed to assess and improve the machine parameters. Here we present the neutron and gamma-ray diagnostics systems which are under design for the initial start-up phase of DTT. The design work benefits from the experience gathered by the community on high power tokamak such as JET. These systems, also called day-1 diagnostics, are: i) Neutron flux monitors which measure the 2.5 and 14 MeV neutron yield s, ii) Neutron/Gamma camera for the reconstruction of the neutron and gamma ray emission profile of the plasma , iii) Hard x-ray monitors for measurements of the bremsstrahlung radiation produced by runway electrons in the 1-40 MeV energy range 1.0 Introduction The Divertor Tokamak Test (DTT) facility, which is under design for construction in Frascati (Italy), will produce neutron yield up to 1.3*10 17 n/s at full power (H-mode scenario).
    [Show full text]
  • Radioisotopes and Radiopharmaceuticals
    RADIOISOTOPES AND RADIOPHARMACEUTICALS Radioisotopes are the unstable form of an element that emits radiation to become a more stable form — they have certain special attributes. These make radioisotopes useful in areas such as medicine, where they are used to develop radiopharmaceuticals, as well as many other industrial applications. THE PRODUCTION OF TECHNETIUM-99m RADIOPHARMACEUTICALS: ONE POSSIBLE ROUTE IRRADIATED U-235 99 TARGETS MO PROCESSING FACILITY HOSPITAL RADIOPHARMACY (MIXING WITH BIOLOGICAL MOLECULES THAT BIND AT DIFFERENT LOCATIONS IN THE 99mTC IS IDEAL FOR DIAGNOSTICS BECAUSE OF BODY, SUPPORTING A WIDE ITS SHORT HALF-LIFE (6 HOURS) AND IDEAL GAMMA EMISSION RANGE OF MEDICAL NUCLEAR APPLICATIONS) REACTOR: 6 HOURS MAKES DISTRIBUTION DIFFICULT 99MO BULK LIQUID TARGET ITS PARENT NUCLIDE, MOLYBDENUM-99, IS PRODUCED; ITS HALF-LIFE (66 HOURS) MAKES 99 99m IRRADIATION IT SUITABLE FOR TRANSPORT MO/ TC GENERATORS 99MO/99mTC GENERATORS ARE PRODUCED AND DISTRIBUTED AROUND THE GLOBE 99MO/99TC GENERATOR MANUFACTURER Radioisotopes can occur naturally or be produced artificially, mainly in research reactors and accelerators. They are used in various fields, including nuclear medicine, where radiopharmaceuticals play a major role. Radiopharmaceuticals are substances that contain a radioisotope, and have properties that make them effective markers in medical diagnostic or therapeutic procedures. The chemical presence of radiopharmaceuticals can relay detailed information to medical professionals that can help in diagnoses and treatments. Eighty percent of all diagnostic medical scans worldwide use 99mTc, and its availability, at present, is dependent on the production of 99Mo in research reactors. Globally, the number of medical procedures involving the use of radioisotopes is growing, with an increasing emphasis on radionuclide therapy using radiopharmaceuticals for the treatment of cancer..
    [Show full text]
  • OPERATIONAL GUIDANCE on HOSPITAL RADIOPHARMACY: a SAFE and EFFECTIVE APPROACH the Following States Are Members of the International Atomic Energy Agency
    OPERATIONAL GUIDANCE ON HOSPITAL RADIOPHARMACY: A SAFE AND EFFECTIVE APPROACH The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GUATEMALA PAKISTAN ALBANIA HAITI PALAU ALGERIA HOLY SEE PANAMA ANGOLA HONDURAS PARAGUAY ARGENTINA HUNGARY PERU ARMENIA ICELAND PHILIPPINES AUSTRALIA INDIA POLAND AUSTRIA INDONESIA PORTUGAL AZERBAIJAN IRAN, ISLAMIC REPUBLIC OF QATAR BANGLADESH IRAQ REPUBLIC OF MOLDOVA BELARUS IRELAND ROMANIA BELGIUM ISRAEL RUSSIAN FEDERATION BELIZE ITALY SAUDI ARABIA BENIN JAMAICA SENEGAL BOLIVIA JAPAN SERBIA BOSNIA AND HERZEGOVINA JORDAN SEYCHELLES BOTSWANA KAZAKHSTAN BRAZIL KENYA SIERRA LEONE BULGARIA KOREA, REPUBLIC OF SINGAPORE BURKINA FASO KUWAIT SLOVAKIA CAMEROON KYRGYZSTAN SLOVENIA CANADA LATVIA SOUTH AFRICA CENTRAL AFRICAN LEBANON SPAIN REPUBLIC LIBERIA SRI LANKA CHAD LIBYAN ARAB JAMAHIRIYA SUDAN CHILE LIECHTENSTEIN SWEDEN CHINA LITHUANIA SWITZERLAND COLOMBIA LUXEMBOURG SYRIAN ARAB REPUBLIC COSTA RICA MADAGASCAR TAJIKISTAN CÔTE D’IVOIRE MALAWI THAILAND CROATIA MALAYSIA THE FORMER YUGOSLAV CUBA MALI REPUBLIC OF MACEDONIA CYPRUS MALTA TUNISIA CZECH REPUBLIC MARSHALL ISLANDS TURKEY DEMOCRATIC REPUBLIC MAURITANIA UGANDA OF THE CONGO MAURITIUS UKRAINE DENMARK MEXICO UNITED ARAB EMIRATES DOMINICAN REPUBLIC MONACO UNITED KINGDOM OF ECUADOR MONGOLIA GREAT BRITAIN AND EGYPT MONTENEGRO NORTHERN IRELAND EL SALVADOR MOROCCO ERITREA MOZAMBIQUE UNITED REPUBLIC ESTONIA MYANMAR OF TANZANIA ETHIOPIA NAMIBIA UNITED STATES OF AMERICA FINLAND NEPAL URUGUAY FRANCE NETHERLANDS UZBEKISTAN GABON NEW ZEALAND VENEZUELA GEORGIA NICARAGUA VIETNAM GERMANY NIGER YEMEN GHANA NIGERIA ZAMBIA GREECE NORWAY ZIMBABWE The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters, New York; it entered into force on 29 July 1957. The Headquarters of the Agency are situated in Vienna.
    [Show full text]
  • Submission to the Nuclear Power Debate Personal Details Kept Confidential
    Submission to the Nuclear power debate Personal details kept confidential __________________________________________________________________________________________ Firstly I wish to say I have very little experience in nuclear energy but am well versed in the renewable energy one. What we need is a sound rational debate on the future energy requirements of Australia. The calls for cessation of nuclear investigations even before a debate begins clearly shows that emotion rather than facts are playing a part in trying to stop the debate. Future energy needs must be compliant to a sound strategy of consistent, persistent energy supply. This cannot come from wind or solar. Lets say for example a large blocking high pressure weather system sits over the Victorian, NSW land masses in late summer- autumn season. We will see low winds for anything up to a week, can the energy market from the other states support the energy needs of these states without coal or gas? I think not. France has a large investment in nuclear energy and charges their citizens around half as much for it than Germany. Sceptics complain about the costs of storage of waste, they do not suggest what is going to happen to all the costs to the environment when renewing of derelict solar panels and wind turbine infrastructure which is already reaching its use by dates. Sceptics also talk about the dangers of nuclear energy using Chernobyl, Three Mile Island and Fuklushima as examples. My goodness given that same rationale then we should have banned flight after the first plane accident or cars after the first car accident.
    [Show full text]
  • Royal Society of Chemistry Input to the Ad Hoc Nuclear
    ROYAL SOCIETY OF CHEMISTRY INPUT TO THE AD HOC NUCLEAR RESEARCH AND DEVELOPMENT ADVISORY BOARD The Royal Society of Chemistry (RSC) was pleased to hear of the instigation of the Ad Hoc Nuclear Research and Development Advisory Board (the Board) following the findings of the House of Lords Science and Technology Committee Inquiry ‘Nuclear Research and Development Capabilities’.1,2 The RSC is the largest organisation in Europe for advancing the chemical sciences. Supported by a network of 47,000 members worldwide and an internationally acclaimed publishing business, its activities span education and training, conferences and science policy, and the promotion of the chemical sciences to the public. This document represents the views of the RSC. The RSC has a duty under its Royal Charter "to serve the public interest" by acting in an independent advisory capacity, and it is in this spirit that this submission is made. To provide input to the Board the RSC has performed a wide consultation with the chemical science community, including members of both our Radiochemistry and Energy Sector Interest Groups and also our Environment Sustainability and Energy Division. September 2012 The Role of Chemistry in a Civil Nuclear Strategy 1 Introduction Chemistry and chemical knowledge is essential in nuclear power generation and nuclear waste management. It is essential that a UK civil nuclear strategy recognises the crucial role that chemistry plays, both in research and innovation and in the development of a strong skills pipeline. As the RSC previously articulated in our response to the House of Lords Inquiry, 3 nuclear power is an important component of our current energy mix.
    [Show full text]
  • Radiation Quick Reference Guide Recommend Contacting Your State Fusion Center
    Domestic Nuclear Detection Office If you encounter something suspicious follow your specific local protocols. Radiation Quick Reference Guide Recommend contacting your state fusion center. DNDO is available 24/7 to assist at 1-877-DNDO-JAC / 1-877-363-6522 JAC Information Line 202-254-7179 Email: [email protected] Nuclear Concerns/ Threats 1. Nuclear Weapon - a device that releases nuclear energy in an ex- Isotopes of Concern for use in RDDs - with common uses plosive manner. Uses Highly Enriched Uranium (HEU) and/or 1. Cobalt-60 – cancer treatment, level/ Plutonium. density gauge, teletherapy, radiography, 2. Improvised Nuclear Device (IND) - a nuclear weapon fabricated food sterilization/irradiation, by a terrorist organization or rogue nation. brachytherapy 2. Iridium-192 – Radiography/non- destructive testing, flaw detection, brachy- therapy “cancer seed”, skin cancer Cobalt 60 sources Uranium “superficial” brachytherapy Plutonium 3. Uranium a. Uranium exists naturally in the earth’s crust. Of the different “isotopes” of uranium, U-235 is the one required to produce a Iridium sentinel and nuclear weapon. gamma camera b. Natural uranium contains a small amount of U-235 (<1%) which Cesium Seeds must be separated in complex extraction processes to create HEU. The predominant uranium isotope is U-238. 3. Cesium-137 - Gauge/level gauge, industrial radiography, brachyther- c. Highly Enriched Uranium (HEU) refers to uranium usable in weap- apy/teletherapy, well logging/density gauges ons due to its enrichment in U-235. 4. Strontium-90 – Radioisotope thermoelectric generator (RTG), fis- d. Approximately 25 kg of HEU is required for a nuclear weapon. sion product, industrial gauges, medical treatment e.
    [Show full text]
  • Use of Radioactive Iodine As a Tracer in Water-Flooding Operations
    . USE of RADIOACTIVE IODINE as a TRACER In WATER-FLOODING OPERATIONS Downloaded from http://onepetro.org/jpt/article-pdf/6/09/117/2237549/spe-349-g.pdf by guest on 27 September 2021 J. WADE WATKINS BUREAU OF MINES MEMBER AIME BARTLESVILLE, OKLA. E. S. MARDOCK WELL SURVEYS, INC. MEMBER AIME TULSA, OKLA. T. P. 3894 ABSTRACT assumed that the physical conditions in the productive formation are homogeneous. Unfortunately, homogen­ The accurate evaluation of reservoir-performance eous conditions rarely, if ever, exist in oil-productive characteristics in the secondary recovery of petroleum formations. The use of a tracer that may be injected by water flooding requires use of a water tracer that into an oil sand and detected quantitatively, or even may be injected into water-input wells and detected at qualitatively, at offsetting oil-production wells provides oil-production wells to supplement data obtained fronz basic data that may be used in determining more core analyses, wellhead tests, and subsurface measure­ accurately the subsurface rates and patterns of flow ments. Radioactive iodine has been used successfully of injected water between wells than is possible by as a water tracer in field tests to determine: (1) rela­ theoretical calculations based on assumed conditions. tive rates and patterns of flow of injected water between Consideration of the data obtained by using a water water-input and oil-production wells and (2) zones of tracer assists in the application of remedial measures excessive water entry into oil-production wells. to water-input wells, such as plugging of channels, or Laboratory evaluations of potential water tracers, selective plugging of highly permeable zones, thereby previous tracer studies, the value of using a radioactive effecting a more uniform flood and a greater ultimate tracer, general field procedures, and the use of surface oil recovery.
    [Show full text]
  • A New Gamma Camera for Positron Emission Tomography
    INIS-mf—11552 A new gamma camera for Positron Emission Tomography NL89C0813 P. SCHOTANUS A new gamma camera for Positron Emission Tomography A new gamma camera for Positron Emission Tomography PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR AAN DE TECHNISCHE UNIVERSITEIT DELFT, OP GEZAG VAN DE RECTOR MAGNIFICUS, PROF.DRS. P.A. SCHENCK, IN HET OPENBAAR TE VERDEDIGEN TEN OVERSTAAN VAN EEN COMMISSIE, AANGEWEZEN DOOR HET COLLEGE VAN DECANEN, OP DINSDAG 20 SEPTEMBER 1988TE 16.00 UUR. DOOR PAUL SCHOTANUS '$ DOCTORANDUS IN DE NATUURKUNDE GEBOREN TE EINDHOVEN Dit proefschrift is goedgekeurd door de promotor Prof.dr. A.H. Wapstra s ••I Sommige boeken schijnen geschreven te zijn.niet opdat men er iets uit zou leren, maar opdat men weten zal, dat de schrijver iets geweten heeft. Goethe Contents page 1 Introduction 1 2 Nuclear diagnostics as a tool in medical science; principles and applications 2.1 The position of nuclear diagnostics in medical science 2 2.2 The detection of radiation in nuclear diagnostics: 5 standard techniques 2.3 Positron emission tomography 7 2.4 Positron emitting isotopes 9 2.5 Examples of radiodiagnostic studies with PET 11 2.6 Comparison of PET with other diagnostic techniques 12 3 Detectors for positron emission tomography 3.1 The absorption d 5H keV annihilation radiation in solids 15 3.2 Scintillators for the detection of annihilation radiation 21 3.3 The detection of scintillation light 23 3.4 Alternative ways to detect annihilation radiation 28 3-5 Determination of the point of annihilation: detector geometry,
    [Show full text]
  • Gamma Cameras
    OECD Health Statistics 2021 Definitions, Sources and Methods Gamma cameras Number of Gamma cameras. A Gamma camera (including Single Photon Emission Computed Tomography, SPECT) is used for a nuclear medicine procedure in which the camera rotates around the patient to register gamma rays emission from an isotope injected to the patient's body. The gathered data are processed by a computer to form a tomographic (cross-sectional) image. Inclusion - SPECT-CT systems using image fusion (superposition of SPECT and CT images). Sources and Methods Australia Source of data: Department of Health. Unpublished data from Location Specific Position Number register. Reference period: Years reported are financial years 1st July to 31st June (e.g. data for 2012 are as at 30th June 2012). Coverage: Data from 2008 onwards represent the number of units approved for billing to Medicare only. Units may be removed from one location and re-registered in another location. Austria Source of data: Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection / Gesundheit Österreich GmbH, Monitoring of medical technology development. Reference period: 31st December. Coverage: - Included are all Gamma cameras units in hospitals as defined by the Austrian Hospital Act (KAKuG) and classified as HP.1 according to the System of Health Accounts (OECD). - The ambulatory sector is included (HP.3). Belgium Source of data: Federal Service of Public Health, DGGS “Organisation of health provisions”; Ministry of the Flemish community and Ministry of the French community. Coverage: - Ambulatory care providers (HP.3): Data on high-tech equipment in cabinets of ambulatory care providers are not available.
    [Show full text]
  • HISTORY Nuclear Medicine Begins with a Boa Constrictor
    HISTORY Nuclear Medicine Begins with a Boa Constrictor Marshal! Brucer J Nucl Med 19: 581-598, 1978 In the beginning, a boa constrictor defecated in and then analyzed the insoluble precipitate. Just as London and the subsequent development of nuclear he suspected, it was almost pure (90.16%) uric medicine was inevitable. It took a little time, but the acid. As a thorough scientist he also determined the 139-yr chain of cause and effect that followed was "proportional number" of 37.5 for urea. ("Propor­ inexorable (7). tional" or "equivalent" weight was the current termi­ One June week in 1815 an exotic animal exhibi­ nology for what we now call "atomic weight.") This tion was held on the Strand in London. A young 37.5 would be used by Friedrich Woehler in his "animal chemist" named William Prout (we would famous 1828 paper on the synthesis of urea. Thus now call him a clinical pathologist) attended this Prout, already the father of clinical pathology, be­ scientific event of the year. While he was viewing a came the grandfather of organic chemistry. boa constrictor recently captured in South America, [Prout was also the first man to use iodine (2 yr the animal defecated and Prout was amazed by what after its discovery in 1814) in the treatment of thy­ he saw. The physiological incident was common­ roid goiter. He considered his greatest success the place, but he was the only person alive who could discovery of muriatic acid, inorganic HC1, in human recognize the material. Just a year earlier he had gastric juice.
    [Show full text]
  • Radiation and Risk: Expert Perspectives Radiation and Risk: Expert Perspectives SP001-1
    Radiation and Risk: Expert Perspectives Radiation and Risk: Expert Perspectives SP001-1 Published by Health Physics Society 1313 Dolley Madison Blvd. Suite 402 McLean, VA 22101 Disclaimer Statements and opinions expressed in publications of the Health Physics Society or in presentations given during its regular meetings are those of the author(s) and do not necessarily reflect the official position of the Health Physics Society, the editors, or the organizations with which the authors are affiliated. The editor(s), publisher, and Society disclaim any responsibility or liability for such material and do not guarantee, warrant, or endorse any product or service mentioned. Official positions of the Society are established only by its Board of Directors. Copyright © 2017 by the Health Physics Society All rights reserved. No part of this publication may be reproduced or distributed in any form, in an electronic retrieval system or otherwise, without prior written permission of the publisher. Printed in the United States of America SP001-1, revised 2017 Radiation and Risk: Expert Perspectives Table of Contents Foreword……………………………………………………………………………………………………………... 2 A Primer on Ionizing Radiation……………………………………………………………………………... 6 Growing Importance of Nuclear Technology in Medicine……………………………………….. 16 Distinguishing Risk: Use and Overuse of Radiation in Medicine………………………………. 22 Nuclear Energy: The Environmental Context…………………………………………………………. 27 Nuclear Power in the United States: Safety, Emergency Response Planning, and Continuous Learning…………………………………………………………………………………………….. 33 Radiation Risk: Used Nuclear Fuel and Radioactive Waste Disposal………………………... 42 Radiation Risk: Communicating to the Public………………………………………………………… 45 After Fukushima: Implications for Public Policy and Communications……………………. 51 Appendix 1: Radiation Units and Measurements……………………………………………………. 57 Appendix 2: Half-Life of Some Radionuclides…………………………………………………………. 58 Bernard L.
    [Show full text]